More on CUS
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $0.32 |
|
|||
| Open | $0.33 | ||||
| 52 Wk High | $0.39 | ||||
| 52 Wk Low | $0.32 | ||||
| Day High | $0.39 | ||||
| Day Low | $0.32 | ||||
| P/E | N/A | ||||
| EPS | $-1.31 | ||||
| Volume | 27,832 | ||||
- Curasight reports tumor uptake in brain cancer trial for uTREAT drug
- Curasight Announces Encouraging Preliminary Data from Phase 1 Trial Evaluating First-in-Class Radiopharmaceutical uTREAT in High-Grade Gliomas®
- Altius Provides 4th Quarter 2025 Project Generation Update
- Curasight doses first patient in brain cancer trial with uTREAT therapy
- Curasight Announces Successful Dosing of First Patient in Phase 1 trial with uTREAT® in Brain Cancer
- Altius Provides 3rd Quarter 2025 Project Generation Update
Entities mentioned with CUS
- Definitive Agreement | View Related Stories »
- Earnings | View Related Stories »
- Dividend | View Related Stories »
- CIBC | View Related Stories »
- Crude Oil | View Related Stories »
- Raising Prices | View Related Stories »
- Credit Suisse | View Related Stories »
- IPO | View Related Stories »
- Show More...
